The purpose of the study is to evaluate how well patients can tolerate the treatment and how effective it is at shrinking the tumor before surgery. Participants receive several doses of the two medicines over a short period, then undergo the planned operation to remove the cancer. After surgery, follow‑up visits include imaging scans such as MRI and routine check‑ups to monitor recovery and any side effects.

Researchers will compare the results with data from patients who receive only one of the medicines or other standard combinations, looking at side‑effect profiles and how much the tumor reduces in size. Blood samples and tissue taken before, during, and after treatment are examined to see how the immune system responds, providing information that may help improve future therapies for this disease.

The purpose of the trial is to explore how well the new ketotifen sprays work and how well they are tolerated compared with the existing cromoglicate spray and the placebo. Participants will use the assigned spray in each nostril every day for up to 12 weeks. They will have a visit before starting treatment, a check‑in after about 4 weeks, and a final visit at 12 weeks to see how symptoms have changed.

Symptoms are measured using a simple rating line called a VAS score, where a person marks how severe their nose problems feel from “no trouble” to “worst possible.” Changes in this score and other symptom counts help show whether the spray makes a noticeable difference. All procedures are designed to be safe and easy to follow.

The purpose of the study is to find out whether the chloramphenicol drops work at least as well as the ciprofloxacin drops in stopping ear discharge in adults with this condition. Participants will use the assigned ear drops for about two weeks. Doctors will examine the ear using a light‑based tool (otoscopy) and take pictures to see if the discharge has cleared. Hearing will be checked with a simple beep test (pure‑tone audiometry) at the start and after the treatment period. Throughout the study, participants will note any irritation, pain, or other side effects and answer questions about how they feel and how satisfied they are with the treatment.

During the study, participants will have a baseline assessment of how well their salivary glands work, using a special imaging test called scintigraphy and a simple saliva‑collection test. After the radiation course, the same tests are repeated to compare any changes. An additional scan using ultrasound will look at the size and texture of the glands, and questionnaires will evaluate any feelings of dry mouth and overall quality of life. Safety will be monitored by recording any side effects or problems at the injection site.

People in the study are placed into one of two groups. One group has the blood flow checked with indocyanine green fluorescence imaging, which means the dye is used so the surgeon can see how blood moves through the flap. The other group is checked with standard clinical assessment, which means the usual way of judging the flap during surgery. After the operation, the flap is followed for a short time to see how it heals and whether any further treatment is needed.

The purpose of the study is to evaluate the effectiveness of CINEOLE compared to mupirocin. CINEOLE is an oral treatment containing cineole, while mupirocin is a medication used through the nose. Participants in the study will undergo a course of treatment to determine how well these substances can reduce the presence of the bacteria in the nasal passages.

During the study, participants will receive one of the treatments for a period of time. Following the treatment, medical evaluations will be conducted to monitor the bacteria levels through a nasal cavity culture, which is a laboratory test used to identify and count the germs present in the nose. Follow-up checks may also be performed to see how long the effects of the treatment last.

The treatment involves an injection of two substances: bupivacaine, a local anesthetic used to numb the area and reduce pain, and dexamethasone, a steroid used to decrease swelling and inflammation. Following the surgery, participants will be monitored for up to 15 days to track pain levels, the healing process, and any potential complications such as a salivary fistula, which is an abnormal opening that allows saliva to leak out of the gland.

The purpose of the study is to determine which of these two drugs provides a better improvement in symptoms related to the nasal polyp disease. Over a period of 12 months, participants will receive one of the medications to see how it affects their breathing, their sense of smell, and their overall quality of life. The study will monitor various changes in symptoms and physical health to evaluate how well each treatment works in a real-world setting.

Participants in the study may receive different doses of Levothyroxine Sodium or a placebo. During the study, monitoring will involve checking levels of hormones such as TSH, T4, and T3 in the blood to see how the body is responding to the treatment. Other factors being observed include eGFR, which is a measurement used to check how well the kidneys are filtering waste from the blood, as well as changes in body weight and BMI. The study will follow participants over several months to observe these changes and assess their health-related quality of life.

The purpose of the study is to see if the body absorbs the two medicines in the same way and at the same speed when people take a single dose of 400mg without eating. This type of study is called a bioequivalence study. During the study, participants will receive one of the two medicines and then, after a break period, they will receive the other medicine. Blood samples will be taken to measure how much of the medicine is in the blood and how long it stays in the body.

The study will also check for any unwanted effects or side effects that might happen after taking the medicines. This includes monitoring any health problems that occur, changes in blood pressure and heart rate, and results from blood and urine tests. The information gathered will help determine if the two medicines work in the same way in the body.

Participants in this study will be randomly assigned to receive either prednisolone or placebo for 10 days. The study is designed so that neither the participants nor the doctors will know who is receiving which treatment. To make the treatments look the same, the prednisolone tablets will be placed inside capsules. During the study, participants will be asked to complete questionnaires that measure dizziness and balance symptoms, as well as how these symptoms affect daily life and overall quality of life. These questionnaires will be completed at different times: 2 weeks, 6 weeks, 3 months, and 12 months after starting the treatment.

The study will also include tests to measure how well the balance system is working. These include a video test that measures eye movements when the head is moved quickly, a timed walking test, measurements of body movement while standing and walking, and a test of standing on a foam pad. Some of these tests will be done at the beginning of the study and again at 6 weeks to see if there are any changes. The main focus will be on comparing the dizziness symptom scores between the two groups at 6 weeks after treatment starts. The study will also look at healthcare use and time off work to understand the broader impact of the treatment.

Participants in this study will be adults who have recently developed acute pharyngitis with significant throat soreness that started within the last 30 hours. The study is designed so that neither the participants nor the researchers know which treatment is being given during the trial. Each person will receive lozenges to dissolve slowly in the mouth. The treatment will last for up to 4 days, during which participants will need to use an electronic device such as a smartphone or tablet to record information about their symptoms.

The main focus of the study is to measure how much the throat soreness improves during the first 2 hours after taking the first lozenge. Researchers will track changes in throat pain intensity by comparing the new lozenges with both placebo and the existing market product. All three types of lozenges are taken in the same way, by placing them in the mouth and allowing them to dissolve slowly. The maximum daily dose is 25.2 milligrams, and the total amount used over the treatment period will not exceed 84 milligrams.

Patients in the study will be randomly assigned to one of two groups. One group will receive two cycles of the combination treatment, while the other group will receive four cycles. A cycle is a period of time during which the medications are given according to a specific schedule. All patients will receive the same medications, but for different lengths of time. The study will measure how the treatment affects quality of life, particularly how well patients can perform their daily activities and roles. Treatment can continue for up to 104 weeks depending on how the cancer responds and how well the patient tolerates the medications.

The study will also look at other important measures such as how long patients live without their cancer getting worse, how long patients survive overall, how many patients have their tumors shrink or disappear, and how long the response to treatment lasts. Patients will be asked to complete questionnaires about their quality of life and stress levels throughout the study to help researchers understand how the different treatment durations affect their daily lives and well-being.

The treatment being tested combines Aspirin Protect (100 mg daily) and Folic Acid (5 mg daily). Some participants will receive these medications, while others will receive a placebo version of one or both medications. The study will track changes in hearing ability over time, particularly focusing on the improvement in hearing after 15 days of treatment.

Participants will be monitored for changes in their hearing through various tests over a period of 6 months. The study will measure hearing improvement, speech understanding, balance function, and quality of life. Regular check-ups will occur at specific intervals throughout the study period to assess how well the treatment is working.

The study will compare three different treatments: DoriDuo lozenges (containing both active ingredients), Mebocaína Anti-Inflam lozenges (containing the same active ingredients), and a placebo. The medications will be given as throat lozenges that dissolve in the mouth. The maximum daily dose will be 25.2 mg, and the treatment will last up to 4 weeks.

During the study, participants will take the assigned lozenges and have their throat soreness levels monitored, particularly in the first two hours after taking the medication. The study is designed to show whether the new medication works better than the placebo and is at least as effective as the existing treatment. All medications will be given in a way that neither the patients nor the doctors know which treatment is being used.

The main purpose of this research is to examine how CBD affects muscle health and energy production in muscle cells (mitochondrial activity) in people with head and neck cancer. Participants will take either Arvisol tablets or placebo tablets along with nutritional supplements for up to 21 days. The maximum daily dose of the medication will be 450 mg.

During the study, researchers will monitor various aspects of muscle health using different measurement techniques. They will assess muscle strength, muscle mass, and overall physical performance. The study will also track how well participants tolerate the treatment by monitoring their appetite and any digestive issues they may experience. Additionally, the research team will evaluate how the cancer responds to treatment using medical imaging.

The main purpose of this study is to determine how effective a short course of mitazalimab treatment is for people with high-risk mouth disorders. During the study, participants will receive the medication through solution for infusion directly into the affected areas of their mouth. The total treatment period will last up to 8 weeks, with specific doses calculated based on body weight.

The study will monitor changes in the mouth conditions over time, particularly focusing on improvements after 6 months of treatment. Participants will need to provide mouth tissue samples and saliva samples throughout the study period. The overall monitoring of participants will continue for several years to track long-term outcomes and any changes in the mouth conditions.

The treatment involves receiving two injections of either ADRC001 or sterile isotone saline (placebo) directly into the salivary glands. These stem cells are derived from fat tissue and are processed in a laboratory to create a specialized cell therapy product. The treatment will be administered over a period of several months to evaluate its effectiveness in improving saliva production.

The study will monitor participants for 8 months to measure changes in their saliva production. The cell therapy being tested represents an innovative approach to treating radiation-induced dry mouth, which can significantly impact quality of life for cancer survivors. This research explores whether these stem cell injections can help restore the natural function of salivary glands that have been damaged by radiation therapy.

Participants in the study will receive either Ropivacaine or Lidocaine during their tonsillectomy. The study will monitor the level of pain experienced by participants after the surgery using a tool called the Visual Analog Scale, which measures pain on a scale from 0 to 10. This will be done several times a day for the first three days after the surgery. The study will also look at how much pain medication participants need during their hospital stay and how quickly they need additional pain relief after the surgery.

The trial will last until the end of 2025, with recruitment of participants expected to start in mid-2025. The study aims to provide valuable information on which local anesthetic is more effective in managing pain after a tonsillectomy, potentially improving recovery experiences for patients with Chronic Tonsillitis.

The purpose of the study is to identify specific markers in the body, known as biomarkers, that can predict how well a patient with CRSwNP will respond to treatment with Mepolizumab. The study will also explore how cells from patients react to Mepolizumab in a laboratory setting, which may help understand the immune responses involved in these conditions. Participants in the study will receive either Mepolizumab or a placebo, and their responses will be monitored over a period of six months.

Throughout the study, researchers will collect information on how the treatment affects symptoms and the immune system. This includes looking at changes in nasal symptoms and examining how cells and molecules in the body respond to the treatment. The study aims to provide insights that could lead to better treatment strategies for people with CRSwNP and CRSsNP in the future.

The purpose of the study is to determine how effective oral corticosteroid therapy is compared to a placebo in treating acute laryngitis among vocal professionals. Participants in the study will be given either Prednisolone or a placebo to take orally. The study will monitor the duration of vocal symptoms and any inflammatory changes in the larynx, especially in the vocal cords, using a procedure called laryngoscopy, which allows doctors to look at the back of the throat, including the voice box.

The study will take place over a period of time, with participants being observed for changes in their symptoms and any improvements in their condition. The goal is to gather information that could help improve treatment options for those suffering from acute laryngitis, particularly individuals who rely on their voice for their profession. The study is expected to continue until the end of 2027.

The purpose of the study is to determine how well nasal lysine-aspirin helps control symptoms and improve quality of life for people with N-ERD. The study will use acetylsalicylic acid (aspirin) and sodium chloride solution as part of the treatment. Participants will receive the medication through the nose over a period of 49 days.

During the study, researchers will track changes in breathing problems, nasal congestion, sense of smell, and overall quality of life. They will also monitor how well asthma symptoms are controlled and any stomach-related side effects that may occur. The treatment involves gradually increasing the medication dose while carefully observing how participants respond to the treatment.

The treatment involves using mometasone furoate, a type of steroid nasal spray, as part of a structured plan to help patients reduce and eventually stop their dependence on decongestant nasal sprays. The study will monitor patients for 12 weeks during the treatment phase and continue following up with them to check if they maintain their progress.

Throughout the study, patients will be asked to keep track of their nasal symptoms and breathing ability. The study will measure how well patients can breathe through their nose, assess their quality of sleep, and examine the inside of their nose to monitor any changes. The research team will also evaluate how many patients successfully stop using decongestant sprays and whether they maintain this improvement over time.

The purpose of the study is to see if this anesthesia technique can help decrease the need for morphine during the first 24 hours after surgery. Patients participating in the study will receive either the anesthesia technique or a placebo, and their morphine use will be monitored. The study will help determine if this method is effective in managing pain after cancer surgery.

Participants will be closely monitored throughout the study to ensure their safety and well-being. The trial will provide valuable information on whether this anesthesia technique can improve pain management for patients undergoing cancer surgery in the throat and neck area.

The purpose of the study is to explore whether BOTOX can improve the quality of life for those suffering from these conditions. Participants will receive injections and will be monitored over a period of time to assess any changes in their symptoms. The study will involve a series of visits where participants will receive either the BOTOX treatment or a placebo, and their progress will be tracked through questionnaires and assessments.

Throughout the study, participants will be asked to report on their tinnitus symptoms, headache levels, and jaw muscle pain. The study aims to determine if there is a significant difference in symptom improvement between those receiving the BOTOX treatment and those receiving the placebo. This research hopes to provide new insights into managing tinnitus and related conditions effectively.

The purpose of this study is to evaluate the effects of reducing the frequency of these medications in patients who have shown stable, partly controlled symptoms. Participants in the study will have been receiving either Dupilumab or Mepolizumab for at least 18 months, with their symptoms being partly controlled for at least 12 months. The study will last for 52 weeks, during which the dosing intervals of the medications will be gradually extended. The main goal is to determine how many patients can maintain partly controlled symptoms with less frequent dosing.

Throughout the study, participants will be monitored to assess changes in their symptoms and overall disease control. This will involve regular check-ups to evaluate nasal blockage, runny nose, facial pain, sense of smell, and the need for additional treatments. The study aims to provide insights into whether patients with CRSwNP can maintain symptom control with less frequent medication, potentially leading to more convenient treatment options in the future.

The purpose of this study is to explore how pembrolizumab works as a treatment before surgery in patients with high-risk thyroid cancer. Participants in the study will receive pembrolizumab to see how it affects their cancer and immune system. The study will involve regular monitoring and assessments to understand the medication’s impact on the cancer and the body’s immune response.

Throughout the study, researchers will collect and analyze samples to learn more about how pembrolizumab influences the immune system and its ability to target cancer cells. This research aims to provide insights into the potential benefits of using pembrolizumab as a treatment option for thyroid cancer, particularly in cases where the cancer is considered high-risk. The study is expected to continue until 2026, with the goal of improving treatment strategies for thyroid cancer patients.

The purpose of the study is to observe changes in symptoms experienced by participants after starting treatment with Tezepelumab. Participants will report on their nasal congestion and other sinus-related symptoms over the course of the study. The study will last for 24 weeks, during which participants will receive regular injections of Tezepelumab and will be asked to keep a diary of their symptoms.

Throughout the study, changes in nasal congestion and other symptoms will be measured to assess the effectiveness of Tezepelumab. Participants will be monitored for any improvements in their condition, such as reduced nasal congestion and better sleep quality. The study aims to provide valuable information on how Tezepelumab can help manage symptoms of Chronic Rhinosinusitis with Nasal Polyposis.

The purpose of the study is to compare the effects of different doses of PF-07976016-87 on body weight in individuals with obesity who are already using Liraglutide. Participants will be randomly assigned to receive either the study medication or a placebo, and the study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The study will last for a period of 16 weeks, during which participants’ body weight changes will be monitored.

Throughout the study, the safety of the participants will be closely monitored, including any side effects or adverse events that may occur. The study will also assess any changes in mood or behavior using specific questionnaires. The goal is to determine the safety and effectiveness of PF-07976016-87 in helping individuals with obesity manage their weight more effectively.

The treatment involves receiving tezepelumab through injection. The medication will be given in doses up to 210 milligrams, with the total treatment period lasting up to 4 months. The total amount of medication received during the study will not exceed 840 milligrams.

The purpose of this study is to understand how tezepelumab affects the protective barrier of the airways in patients who have severe asthma, both with and without nasal polyps. The research will examine how the airways respond to various substances that can cause irritation. This will help researchers better understand how the medication works to protect the airways in these conditions.

The purpose of the study is to determine if patients who have been symptom-free for at least 12 months can safely stop their treatment without their symptoms returning. Participants in the study will have been receiving either Mepolizumab or Dupilumab regularly and will be monitored to see if they can maintain their symptom-free status after discontinuing the medication. The study will compare the outcomes of patients who stop treatment with those who continue, to see if there are any differences based on the medication used.

Throughout the study, participants will be closely observed to ensure their condition remains stable. The main goal is to find out what percentage of patients can stop their biologic treatment and still remain in complete remission, meaning they have no symptoms. The study will also look at whether there are any differences in outcomes based on which drug the patients were treated with. This research aims to provide valuable insights into the long-term management of Chronic Rhinosinusitis with Nasal Polyps.

The purpose of the study is to evaluate how well this treatment improves hearing in patients who have not responded to other treatments, such as oral or ear injections of steroids. Participants in the study will receive either the triamcinolone acetonide injection or a placebo. The study will observe changes in hearing ability over a period of time, using tests that measure how well participants can hear different tones and understand speech.

Throughout the study, participants will undergo various hearing tests, including the pure tone audiometry, which measures the ability to hear sounds at different pitches, and speech tests to assess how well they can understand spoken words. The study aims to provide insights into the effectiveness of this treatment for those with persistent hearing loss after other therapies have failed.

The purpose of the study is to see how well Lebrikizumab works in reducing nasal congestion and the size of nasal polyps over a period of 24 weeks. Participants will be randomly assigned to receive either the treatment or the placebo, and neither the participants nor the researchers will know who is receiving which, to ensure unbiased results. The study will involve regular check-ups and assessments to monitor the condition of the participants and the effects of the treatment.

Throughout the study, participants will be asked to report their nasal congestion symptoms using a simple scale, and the size of their nasal polyps will be evaluated through a procedure called nasal endoscopy, which involves using a small camera to look inside the nose. The study aims to provide valuable information on whether Lebrikizumab can be an effective treatment option for people with Chronic Rhinosinusitis with Nasal Polyps.

The purpose of the study is to assess how well Lebrikizumab can reduce the total nasal symptoms in adults with perennial allergic rhinitis over a period of 16 weeks. Participants will be randomly assigned to receive either the medication or the placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study, which helps ensure the results are unbiased.

Throughout the study, participants will attend regular visits to monitor their symptoms and overall health. The main focus will be on changes in the severity of nasal symptoms from the start of the study to the end of the 16-week period. The study aims to provide valuable information on the potential benefits of Lebrikizumab for individuals suffering from perennial allergic rhinitis.

The purpose of this study is to understand how Dupilumab affects ear symptoms and hearing function in patients with these conditions. Participants in the study will receive Dupilumab through subcutaneous injection, which means the medication is injected under the skin. The study will observe changes in symptoms and hearing over a period of time, specifically looking at how these change from the start of the treatment to 6 or 12 months later. Participants will be asked to complete questionnaires about their symptoms and undergo hearing tests to track any improvements or changes.

Throughout the study, researchers will monitor the participants’ progress by comparing their initial condition with their condition after receiving Dupilumab for several months. This will help determine the effectiveness of the treatment in managing symptoms related to chronic rhinosinusitis with nasal polyps and eosinophilic otitis media. The study aims to provide valuable insights into how Dupilumab can potentially improve the quality of life for individuals suffering from these conditions.

Participants in the study will be adults who are receiving cisplatin as part of their cancer treatment. The study will involve taking SENS-401 at a dose of 43.5 mg twice a day for up to 23 weeks. The effectiveness of SENS-401 in preventing hearing loss will be assessed four weeks after the last dose of cisplatin. Some participants will receive a placebo instead of SENS-401 to compare the outcomes.

The study will monitor changes in hearing ability by measuring hearing thresholds, which are the quietest sounds a person can hear, at various frequencies. This will help determine if SENS-401 is effective in protecting against hearing loss. The trial is expected to continue until March 2025, with participants being recruited since December 2022.

Participants in the study will receive either mepolizumab alone or a combination of surgery and mepolizumab. The surgery involved is called Functional Endoscopic Sinus Surgery (FESS), which is a procedure to remove nasal polyps and improve sinus drainage. The study will follow participants for 6 to 12 months to observe changes in their symptoms and overall condition.

The main focus of the study is to see how the treatment affects the severity of symptoms, including nasal polyps and sense of smell. The study will measure changes in a symptom score known as SNOT-22, which helps assess the impact of the condition on daily life. The goal is to determine the most effective way to manage CRSwNP and improve patients’ quality of life.

The purpose of the study is to see how these treatments affect the body’s immune system, specifically looking at a type of immune cell called a T-cell. The study will last for about three weeks, during which participants will receive one of the treatments before starting their standard cancer treatment. The study will monitor the safety and effects of these treatments on the cancer and the immune system.

Participants will be closely observed to see how their bodies respond to the treatment, including any changes in their cancer and any side effects they might experience. The study aims to gather information on how well these treatments work on their own before the usual cancer treatments begin. This research could help improve future treatment options for people with head and neck cancer.